370880-82-3

Usage

Uses

Used in Organic Synthesis:
N-Boc-6-azaindole is used as a building block in organic synthesis for its ability to facilitate the creation of complex molecular structures. The N-Boc group enhances the stability and reactivity control of the molecule, making it a valuable component in the synthesis of various organic compounds.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, N-Boc-6-azaindole is utilized as a precursor to biologically active compounds. Its protective N-Boc group allows for the development of pharmaceuticals with specific therapeutic properties, contributing to drug discovery and the advancement of novel treatments.
Used in Pharmaceutical Development:
N-Boc-6-azaindole is employed as a key intermediate in the synthesis of pharmaceuticals. Its role in creating diverse drug candidates highlights its importance in the development of new medications with potential therapeutic applications.
Used in Agrochemical Development:
Similarly, in agrochemical development, N-Boc-6-azaindole serves as a crucial building block for the creation of agrochemicals. Its versatility and protective N-Boc group make it suitable for the synthesis of compounds used in agriculture to improve crop protection and yield.
Overall, N-Boc-6-azaindole's applications span across various scientific and industrial fields, underpinning its significance in the creation and development of new chemical entities with practical utility.

Upstream product

• 124-63-0 methanesulfonyl chloride 
• 185139-01-9 tert-butyl 2-hydroxy-2,3-dihydro-1H-pyrrolo[2,3-c]pyridine-1-carboxylate 
• 1346809-07-1 tert-butyl oxazol-5-ylcarbamate 
• 271-29-4 6-azaindole 
• 34619-03-9 tert-butyldicarbonate 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 169750-88-3 tert-butyl 2,3,3a,4,5,6,7,7a-octahydropyrrolo[2,3-c]pyridine-1-carboxylate 
• 1174038-67-5 tert-butyl 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo [2,3-c]pyridine-1-carboxylate 
• 1374243-44-3 tert-butyl 6-(2-(3,5-dichlorophenylamino)acetyl)octahydro-1H-pyrrolo[2,3-c]pyridine-1-carboxylate 
• 1374243-70-5 C₁₅H₁₉Cl₂N₃O 
• 1374239-82-3 2-(3,5-dichlorophenylamino)-1-[1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-octahydro-1H-pyrrolo[2,3-c]pyridin-6-yl]ethanone 
• 1374239-83-4 1-(1-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)tetrahydro-1H-pyrrolo[2,3-c]pyridine-6(2H,7H,7aH)-yl)-2-(3,5-dichlorophenylamino)ethanone 
• 1374243-45-4 C₂₆H₃₅Cl₂N₇O₂Si 
• 1374240-00-2 1-((3aS,7aS)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)tetrahydro-1H-pyrrolo[2,3-c]pyridine-6(2H,7H,7aH)-yl)-2-(3,5-dichlorophenylamino)ethanone 
• 1374240-01-3 1-((3aR,7aR)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)tetrahydro-1H-pyrrolo[2,3-c]pyridine-6(2H,7H,7aH)-yl)-2-(3,5-dichlorophenylamino)ethanone 
• 1438081-00-5 tert-butyl 6-(3-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)propyl)octahydro-1H-pyrrolo[2,3-c] pyridine-1-carboxylate 
• 1438072-77-5 N-(3-chloro-4-fluorophenyl)-6-(3-(hexahydro-1H-pyrrolo[2,3-c]pyridin-6(2H)-yl)propoxy)-7-methoxyquinazolin-4-amine 
• 1438072-83-3 N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(1-methylhexahydro-1H-pyrrolo[2,3-c]pyridin-6(2H)-yl)propoxy)quinazolin-4-amine 
• 949559-11-9 (3aS,7aR)-tert-butyl octahydro-1H-pyrrolo[2,3-c]pyridine-1-carboxylate 
• 949559-11-9 (3aR,7aS)-tert-butyl octahydro-1H-pyrrolo[2,3-c]pyridine-1-carboxylate 

Relevant academic research and scientific papers

QUINAZOLINE COMPOUNDS, PREPARATION METHODS AND USES THEREOF

Provided herein are novel compounds, for example, compounds having a Formula (I), Formula (II), or Formula (III), or a pharmaceutically acceptable salt thereof. Also provided herein are methods of preparing the compounds and methods of using the compounds, for example, in inhibiting KRAS G12D in a cancer cell, and/or in treating various cancer such as pancreatic cancer, colorectal cancer, lung cancer or endometrial cancer.

Formation of 6-Azaindoles by Intramolecular Diels-Alder Reaction of Oxazoles and Total Synthesis of Marinoquinoline A

A new variant of the intramolecular Diels-Alder oxazole (IMDAO) cycloaddition that provides direct access to 6-azaindoles was developed. The IMDAO reaction was applied in a total synthesis of the aminophenylpyrrole-derived alkaloid marinoquinoline A, also

HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES

Provided herein are Heterocyclic compounds of formula (I): and pharmaceutically acceptable salts, tautomers, isotopologues, or stereoisomers thereof, wherein W, X, Y, R1, R2, and RN are as defined herein, compositions comprising an effective amount of a Heterocyclic Compound, and methods for treating or preventing animal and human filarial worm infections and diseases.

Design, synthesis and biological evaluation of 7-chloro-9h-pyrimido[4,5-b]indole-based glycogen synthase kinase-3β inhibitors

Glycogen synthase kinase-3β (GSK-3β) represents a relevant drug target for the treatment of neurodegenerative pathologies including Alzheimer’s disease. We herein report on the optimization of a novel class of GSK-3β inhibitors based on the tofacitinib-derived screen hit 3-((3R,4R)-3-((7-chloro-9H-pyrimido[4,5-b]indol-4-yl)(methyl)amino)-4-methylpiperidin-1-yl)-3-oxopropanenitrile (1). We synthesized a series of 19 novel 7-chloro-9H-pyrimido[4,5-b]indole-based derivatives and studied their structure–activity relationships with focus on the cyanoacetyl piperidine moiety. We unveiled the crucial role of the nitrile group and its importance for the activity of this compound series. A successful rigidization approach afforded 3-(3aRS,7aSR)-(1-(7-chloro-9H-pyrimido[4,5-b]indol-4-yl)octahydro-6H-pyrrolo[2,3-c]pyridin-6-yl)-propanenitrile (24), which displayed an IC50 value of 130 nM on GSK-3β and was further characterized by its metabolic stability. Finally, we disclosed the putative binding modes of the most potent inhibitors within the ATP binding site of GSK-3β by 1 μs molecular dynamics simulations.

PYRROLO[2,3-B]PYRIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER

The present application relates to a compound of Formula I, or a salt, hydrate or solvate thereof, as defined herein. The present compounds are found to have pharmacological effects, particularly at MRCK. Further provided are pharmaceutical compositions comprising said compounds. The present invention also relates to the use of these compounds as therapeutic agents, in particular, for the treatment and/or prevention of proliferative diseases, such as cancer.

ALANINE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE

The description relates to inhibitors of Apoptosis Proteins (TAPs) binding compounds, including Afunctional compounds comprising the same, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the description provides compounds, which contain on one end a ligand which binds to the IAP E3 ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. Compounds can be synthesized that exhibit a broad range of pharmacological activities consistent with the degradation/inhibition of targeted polypeptides of nearly any type.

ISOQUINOLINESULFONYL DERIVATIVE AS RHO KINASE INHIBITOR

The present invention discloses a class of isoquinolinesulfonyl derivatives as RHO kinase inhibitors, and pharmaceutical compositions thereof, and relates to pharmaceutically acceptable uses thereof. Specifically, the present invention relates to a compound as represented by formula (I), or a pharmaceutically acceptable salt thereof.

DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A BICYCLO MOIETY

The disclosure provides compounds having formula (I), wherein the substituents are as defined herein. The compounds are useful for modulating the dopamine D3 receptor and for treating conditions associated therewith, such as addictions, drug dependency, and psychiatric conditions.

6,5-BICYCLIC OCTAHYDROPYRROLOPYRIDINE OREXIN RECEPTOR ANTAGONISTS

The present invention is directed to 6,5-bicyclic octahydropyrrolopyridine compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.

PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL AND PYR-ROLO[2,3-D]PYRIDINYL ACRYLAMIDES

The present invention provides pharmaceutically active pyrrolo[2,3-d]pyrimidinyl and pyrrolo[2,3-d]pyridinyl acrylamides and analogues thereof. Such compounds are useful for inhibiting Janus Kinase (JAK). This invention also is directed to compositions comprising methods for making such compounds, and methods for treating and preventing conditions mediated by JAK.